Damage to myelin, the protective sheath surrounding nerve fibers, impairs the brain's ability to transmit signals efficiently ...

When activated by semaphorin-3A (SEM3A), which is upregulated in MS lesions, the heterodimer inhibits two critical steps of remyelination: the differentiation of oligodendrocyte progenitor cells ...

A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...

Multiple sclerosis (MS) typically begins with a ... There are currently no approved therapies aimed at promoting remyelination. Previous work has shown that the protein kinase C (PKC)–modulating ...

There is an urgent and unmet need for effective therapeutics that limit disability progression in MS, with remyelination offering a promising neuroprotective treatment. Whilst GPR17 antagonists ...

MS was long considered a T-cell mediated disorder ... coupled with failed compensatory mechanisms like neuroplasticity and ...

There is an urgent and unmet need for effective therapeutics that limit disability progression in MS, with remyelination offering a promising neuroprotective treatment. Whilst GPR17 antagonists ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

The small molecule therapeutic is designed to promote remyelination in neurological diseases, including multiple sclerosis (MS). PTD802 is a selective GPR17 antagonist developed under an exclusive ...